Free Trial
NYSE:ZBH

Zimmer Biomet Q2 2025 Earnings Report

Zimmer Biomet logo
$93.88 -1.27 (-1.33%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$93.76 -0.12 (-0.13%)
As of 07/11/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet EPS Results

Actual EPS
N/A
Consensus EPS
$1.99
Beat/Miss
N/A
One Year Ago EPS
N/A

Zimmer Biomet Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.06 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zimmer Biomet Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Zimmer Biomet Earnings Headlines

Citi Remains a Hold on Zimmer Biomet Holdings (ZBH)
Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $96.00 at Evercore ISI
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
ZBH - Zimmer Biomet Holdings Inc Chart | Morningstar
See More Zimmer Biomet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zimmer Biomet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zimmer Biomet and other key companies, straight to your email.

About Zimmer Biomet

Zimmer Biomet (NYSE:ZBH) (NYSE: ZBH) is a global leader in musculoskeletal healthcare, specializing in the design, manufacture and marketing of orthopedic reconstructive products, sports medicine, biologics, spinal and trauma devices, and dental implants. The company’s portfolio addresses a broad range of conditions affecting bones, joints and soft tissue, offering solutions intended to improve patient mobility and quality of life. Zimmer Biomet’s offerings span from joint replacement systems to surgical support products and bone cement, catering to the needs of healthcare professionals worldwide.

Formed through the 2015 merger of Zimmer Holdings, Inc. (founded in 1927) and Biomet, Inc. (founded in 1977), Zimmer Biomet is headquartered in Warsaw, Indiana, often referred to as the “Orthopedic Capital of the World.” Under the leadership of President and Chief Executive Officer Bryan Hanson, the company has continued to pursue innovation in musculoskeletal care and expand its product lines through strategic acquisitions and internal research and development efforts.

The company’s product suite includes hip, knee, shoulder and elbow replacement systems, trauma fixation devices, dental and craniomaxillofacial implants, and spinal technologies. Zimmer Biomet also invests in digital surgery, personalized implant solutions and robotic-assisted platforms to enhance surgical precision and outcomes. By integrating advanced imaging, surgical planning software and navigation tools, the company aims to deliver comprehensive treatment solutions across the continuum of care.

Zimmer Biomet operates in more than 100 countries, with manufacturing and research facilities located in North America, Europe, Asia and Latin America. The company serves hospitals, ambulatory surgery centers and dental practices, forging partnerships with healthcare providers to address the evolving needs of patients and clinicians. With a focus on global reach and local engagement, Zimmer Biomet continues to pursue opportunities in emerging markets while reinforcing its position in established healthcare systems.

View Zimmer Biomet Profile

More Earnings Resources from MarketBeat